LIMN
Liminatus Pharma·NASDAQ
--
--(--)
--
--(--)
7.17 / 10
Outperform
Fund flow metrics score 7.17/10, reflecting robust capital movement with positive net inflows across block, small, medium, and large orders. The sentiment is rated Outperform, indicating that money is generally flowing in. However, the overall fund-flow trend is labeled negative in the pattern data, underscoring a tug-of-war between inflows and outflows. This dynamic aligns with the neutral analyst coverage and adds another layer of uncertainty to the stock's near-term direction.
Fund Flow Rating
What is the market sentiment for LIMN?
- LIMN holds a Neutral analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 7.17/10 (Outperform).
